First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept

• Kimberly VelthuisNetherlands Pharmacovigilance Centre Lareb
• Naomi T. JessurunNetherlands Pharmacovigilance Centre Lareb
• Thi D.M. NguyenNetherlands Pharmacovigilance Centre Lareb
• Joep H. G. SchollNetherlands Pharmacovigilance Centre Lareb
• Jurriaan R.G. JansenNetherlands Pharmacovigilance Centre Lareb
• Jette A. van LintNetherlands Pharmacovigilance Centre Lareb
• Leanne J. KosseRadboud University Nijmegen
• Peter M. ten KloosterUniversity of Twente
• Harald E. VonkemanMedisch Spectrum Twente